AI-assisted analysis based on the official CRS summary. Source version: Aug 27, 2026. Analysis updated: Sep 20, 2026.
01 — The Text
What.
- Adds xylazine (tranq) to Schedule III of the Controlled Substances Act, placing it in the same category as ketamine and buprenorphine
- Xylazine is a nonopioid sedative approved for animal use that has been increasingly found mixed with fentanyl in illicit drug trafficking
- Requires xylazine transactions to be tracked in the DEA's drug reporting system
- Establishes criminal penalties for manufacturing, distributing, dispensing, or possessing xylazine with intent to distribute for illicit use
- Exempts veterinary and pharmacy dispensing for legitimate animal use from CSA registration requirements
02 — The Stakes
So what?
- Classification subjects xylazine to Schedule III penalties, which are less severe than Schedule I or II but still carry criminal liability for illicit activity
- Exempts manufacturers from certain physical security requirements under the CSA
- Exempts lawful animal-use xylazine from registration, limiting regulatory burden on veterinary and wildlife programs
- Requires DEA and FDA to report on prevalence, impact, and trafficking patterns of illicit xylazine—results not yet available
03 — The Path
Now what?
- House passed the bill on suspension of the rules by voice vote on September 15, 2026
- Senate received the bill September 16, 2026 and placed it on the Legislative Calendar (Calendar No. 623)
- No subsequent Senate votes or floor action has been recorded
Legislative History
Actions.
- Sep 16, 2026 — Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623.
- Sep 15, 2026 — On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5671-5672)
- Sep 15, 2026 — Considered under suspension of the rules. (consideration: CR H5671-5673)
- Sep 15, 2026 — Motion to reconsider laid on the table Agreed to without objection.
- Sep 15, 2026 — On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Sep 15, 2026 — Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
- Sep 15, 2026 — DEBATE - The House proceeded with forty minutes of debate on H.R. 1266.
- Sep 15, 2026 — Considered under suspension of the rules.